Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Tuesday, August 1st.
A number of other brokerages also recently issued reports on CYTX. B. Riley reaffirmed a “buy” rating and issued a $2.30 price objective on shares of Cytori Therapeutics in a research report on Wednesday, May 10th. Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Tuesday, July 11th. Finally, Maxim Group set a $10.00 price objective on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 31st.
Shares of Cytori Therapeutics (NASDAQ:CYTX) traded down 4.204% during trading on Tuesday, hitting $0.335. 887,249 shares of the stock traded hands. Cytori Therapeutics has a 12 month low of $0.31 and a 12 month high of $2.29. The stock’s market cap is $10.88 million. The firm’s 50-day moving average price is $0.80 and its 200-day moving average price is $1.21.
Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The company’s revenue for the quarter was down 18.2% on a year-over-year basis. During the same period last year, the business posted ($0.43) EPS. Analysts anticipate that Cytori Therapeutics will post ($0.83) EPS for the current year.
WARNING: This article was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/08/11/cytori-therapeutics-inc-cytx-downgraded-to-strong-sell-at-valuengine-updated.html.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. raised its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 612,304 shares of the biotechnology company’s stock after buying an additional 275,653 shares during the period. Vanguard Group Inc. owned about 1.89% of Cytori Therapeutics worth $674,000 as of its most recent filing with the SEC. 10.01% of the stock is currently owned by institutional investors and hedge funds.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.